Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern

The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding antibody responses to Ad26.COV2.S vaccination are stable for 6 months post-vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitchin, Dale, Richardson, Simone I., van der Mescht, Mieke A., Motlou, Thopisang, Mzindle, Nonkululeko, Moyo-Gwete, Thandeka, Makhado, Zanele, Ayres, Frances, Manamela, Nelia P., Spencer, Holly, Lambson, Bronwen, Oosthuysen, Brent, Kaldine, Haajira, du Pisanie, Marizane, Mennen, Mathilda, Skelem, Sango, Williams, Noleen, Ntusi, Ntobeko A.B., Burgers, Wendy A., Gray, Glenda G., Bekker, Linda-Gail, Boswell, Michael T., Rossouw, Theresa M., Ueckermann, Veronica, Moore, Penny L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828412/
https://www.ncbi.nlm.nih.gov/pubmed/35474744
http://dx.doi.org/10.1016/j.xcrm.2022.100535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828412/
https://www.ncbi.nlm.nih.gov/pubmed/35474744
http://dx.doi.org/10.1016/j.xcrm.2022.100535

Ejemplares similares